Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn how effective the combination of the
drugs imatinib mesylate (Gleevec®) and docetaxel (Taxotere®) is in treating non-small cell
lung cancer (NSCLC). The safety and tolerability of this drug combination will also be
studied.